Additionally, the genes that are distinctly expressed in liver CD90+CSCs but not in CD90+NTSCs, such as GPC3, could be promising candidates for immunotherapy, which could eliminate liver cancer stem cells and adult cancer cells without inducing damage to normal liver cells. Here, THY1 is linked to liver cancer.